Dr. rer. nat. Stefanie Göllner

Academic Training

1998-2003                  Studies of Biology, Friedrich-Schiller-University Jena

Scientific Certificates

2007                            PhD (Summa cum laude), Friedrich-Schiller-University Jena

2003                            Diploma in Biology, Friedrich-Schiller-University Jena

Professional Career

Since 2020                Senior Scientist (permanent position) in the lab of P. Michl, Dept. of Internal
                                   Medicine I, University Hospital Halle (Saale),
                                   Martin-Luther-University Halle (Saale) (Germany)*

Since 2017                 Senior Scientist/Scientific Manager (permanent position) in the lab of
                                   C. Müller-Tidow, Dept. Hematology, Oncology and Rheumatology,
                                   University Hospital and Medical Faculty Heidelberg,
                                   Heidelberg University, Heidelberg (Germany)*

2014-2017                  Staff Scientist (permanent position) in the lab of C. Müller-Tidow,
                                   Dept. Hematology and Oncology, University Hospital Halle
                                   (Saale), Martin-Luther-University Halle (Saale) (Germany)

2008-2014                 Postdoctoral Research Fellow in the lab of C. Müller-Tidow,
                                   Dept. Hematology Oncology and Pneumology, University Hospital
                                   Münster, Westfälische Wilhelms-University Münster (Germany)

2007-2008                Research Associate, Friedrich-Löffler-Institut, Jena (Germany)

*Double- affiliation

Scientific Activities, Honors, Awards

2017                           Best Paper Award, Deutsche Jose-Carreras-Leukämie-Stiftung (DJCLS)

2017                           Leukemia Clinical Research Award, Deutsche Gesellschaft für
                                   Hämatologie und Onkologie (DGHO)

2013                           Best Abstract Achievment Award, American Society of Hematology (ASH)

2004-2007                 PhD stipend, H. Wilhelm Schaumann Stiftung

Most important Publications

1. Scheller M, Ludwig A K, Göllner S, Rohde C, Krämer S , Stäble S, Janssen M, Müller J-A, He L, Bäumer N, Arnold C, Gerß J, Schönung M, Thiede C, Niederwieser C, Niederwieser D, Serve H, Berdel W E, Thiem U, Hemmerling I, Leuschner F, Plass C, Schlesner M, Zaugg J, Milsom M, Trumpp A, Pabst C, Lipka D B, Müller-Tidow C. HotspotDNMT3A mutations in Clonal Hematopoiesis and Acute Myeloid Leukemia sensitize cells to Azacytidine via viral mimicry. Nat Cancer. 2021; accepted for publication
2. Wass M, Göllner S, Besenbeck B, Schlenk R F, Mundmann P, Göthert J R, Noppeney R, Schliemann C, Mikesch J H, Lenz G, Dugas M, Wermke M, Röllig C, Bornhäuser M, Serve H, Platzbecker U, Foerster K I, Burhenne J, Haefeli W E, Müller L P, Binder M, Pabst C Müller-Tidow C. A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy. Leukemia 2020; Jun 19: 1-11.
3. Cui C, Liu Y, Gerloff D,  Rohde C,  Pauli C, Köhn M, Misiak D, Oellerich T, Schwartz S, Schmidt L-H, Wiewrodt R, Marra A , Hillejan L,  Bartel F, Wickenhauser C, Hüttelmaier S, Göllner S, Zhou F, Edemir B, Müller-Tidow C. NOP10 predicts lung cancer prognosis and its associated small nucleolar RNAs drive proliferation and migration. Oncogene. 2020; Dec 7. doi: 10.1038/s41388-020-01570-y. Online ahead of print
4. von Heyking K, Calzada-Wack J, Göllner S, Neff F, Schmidt O, Hensel T, Schirmer D, Fasan A, Esposito I, Müller-Tidow C, Sorensen PH, Burdach S, Richter GHS. The endochondral bone protein CHM1 sustains an undifferentiated, invasive phenotype, promoting lung metastasis in Ewing sarcoma. Mol Oncol. 2017; 11:1288-1301.
5. Zhou F, Liu Y, Rohde C, Pauli C, Gerloff D, Köhn M, Misiak D, Bäumer N, Cui C, Göllner S, Oellerich T, Serve H, Garcia-Cuellar MP, Slany R, Maciejewski JP, Przychodzen B, Seliger B, Klein HU, Bartenhagen C, Berdel WE, Dugas M, Taketo MM, Farouq D, Schwartz S, Regev A, Hébert J, Sauvageau G, Pabst C, Hüttelmaier S, Müller-Tidow C AML1-ETO requires enhanced C/D box snoRNA/RNP formation to induce self-renewal and leukaemia. Nat Cell Biol. 2017; 19: 844-855.
6. Mohr S, Doebele C, Comoglio F, Berg T, Beck J, Bohnenberger H, Alexe G, Corso J, Ströbel P, Wachter A, Beissbarth T, Schnütgen F, Cremer A, Haetscher N, Göllner S, Rouhi A, Palmqvist L, Rieger MA, Schroeder T, Bönig H, Müller-Tidow C, Kuchenbauer F, Schütz E, Green AR, Urlaub H, Stegmaier K, Humphries RK, Serve H & Oellerich T (2017) Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing miR-146a in Acute Myeloid Leukemia. Cancer Cell. 2017;31: 549-562.
7. Göllner S& Müller-Tidow C. Inhibition of EZH2 degradation as a novel approach to overcome drug resistance in acute myeloid leukemia. Mol Cell Oncol. 2017; 4:e1291396.
8. Göllner, S, Oellerich, T, Agrawal-Singh, S, Schenk, T, Klein, HU, Rohde, C, Pabst, C, Sauer, T, Lerdrup, M, Tavor, S, Stolzel, F, Herold, S, Ehninger, G, Kohler, G, Pan, KT, Urlaub, H, Serve, H, Dugas, M, Spiekermann, K, Vick, B, Jeremias, I, Berdel, W E, Hansen, K, Zelent, A, Wickenhauser, C, Müller, LP, Thiede, C, Müller-Tidow, C. Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia, Nat Med. 2017;23: 69-78.
9. Schenk T, Chen WC, Göllner S, Howell L, Jin L, Hebestreit K, Klein HU, Popescu AC, Burnett A, Mills K, Casero RA Jr, Marton L, Woster P, Minden MD, Dugas M, Wang JC, Dick JE, Müller-Tidow C, Petrie K, Zelent A. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia.Nat Med.2012; 18: 605-611.
10. Goellner S, Steinbach D, Schenk T, Gruhn B, Zintl F, Ramsay E & Saluz HP. Childhood acute myelogenous leukaemia: association between PRAME, apoptosis- and MDR-related gene expression. Eur J Cancer. 2006; 42: 2807-2814.